Kyverna Therapeutics, Inc. (KYTX)

NASDAQ: KYTX · IEX Real-Time Price · USD

9.84

+0.94 (10.56%)

At close: Jul 26, 2024, 4:00 PM

9.65

-0.19 (-1.93%)

After-hours: Jul 26, 2024, 4:48 PM EDT

Kyverna Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	-	-	7.03	5.66
Revenue Growth (YoY)	-	-	24.20%	-
Cost of Revenue	63.69	49.92	28.4	25.85
Gross Profit	-63.69	-49.92	-21.38	-20.2
Selling, General & Admin	15.53	12.48	8.01	6.15
Operating Expenses	15.53	12.48	8.01	6.15
Operating Income	-79.22	-62.41	-29.38	-26.35
Interest Expense	-0.19	-0.19	-0.07	-0
Interest & Investment Income	4.67	2.28	0.57	0
Other Non Operating Income (Expenses)	-0.08	-0.06	-0.01	-0
EBT Excluding Unusual Items	-74.82	-	-	-
Other Unusual Items	-1.1	-	-	-
Pretax Income	-75.92	-60.37	-28.89	-26.35
Net Income	-75.92	-60.37	-28.89	-26.35
Net Income to Common	-75.92	-60.37	-28.89	-26.35
Shares Outstanding (Basic)	6	1	0	0
Shares Outstanding (Diluted)	6	1	0	0
Shares Change (YoY)	2300.19%	47.89%	71.30%	-
EPS (Basic)	-11.90	-89.61	-63.43	-99.10
EPS (Diluted)	-11.90	-89.61	-63.43	-99.10
Free Cash Flow	-67.61	-53.03	-36.88	-23.44
Free Cash Flow Per Share	-10.59	-78.73	-80.97	-88.17
Operating Margin	-	-	-418.28%	-465.81%
Free Cash Flow Margin	-	-	-525.00%	-414.50%
EBITDA	-78.31	-61.54	-28.61	-25.76
D&A For EBITDA	0.91	0.87	0.78	0.59
EBIT	-79.22	-62.41	-29.38	-26.35

Source: S&P Capital IQ. Standard template.